Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants

PHASE4CompletedINTERVENTIONAL

Enrollment

2,590

Participants

Timeline

Start Date

November 2, 2004

Primary Completion Date

August 23, 2007

Study Completion Date

August 23, 2007

Conditions

DiphtheriaTetanusPoliomyelitisAcellular PertussisHaemophilus Influenzae Type bDiphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines

Interventions

BIOLOGICAL

GSK Biologicals' combined DTPa-IPV/Hib vaccine

4 intramuscular injections

Trial Locations (1)

GSK Investigational Site, Singapore